T
he American Diabetes Association (ADA) first released its Standards of Medical Care in Diabetes for health professionals in 1989. These practice guidelines provide an extensive set of evidence-based recommendations that are updated annually for the diagnosis and management of patients with diabetes. The 2017 Standards cover all aspects of patient care (1) ; this guideline synopsis focuses on pharmacologic approaches for patients with type 2 diabetes.
GUIDELINE DEVELOPMENT AND EVIDENCE GRADING
To develop the 2017 Standards, the ADA Professional Practice Committee, which comprises physicians, adult and pediatric endocrinologists, diabetes educators, registered dietitians, epidemiologists, and public health experts, systematically searched MEDLINE from 1 January 2016 (date of last previous search) to November 2016 . The committee revised recommendations based on the new evidence or, in some cases, to clarify prior ones or match the strength of the wording to the strength of the evidence. It also solicited feedback from the larger clinical community.
The recommendations are rated as A, B, C, or E. Those with an A rating are based on large, welldesigned, multicenter clinical trials or high-quality meta-analyses. Recommendations with lower-quality evidence may be equally important and are based on well-conducted cohort studies (B rating) or uncontrolled studies (C rating). Those assigned an E rating are consensus recommendations for which there is no evidence from clinical trials, in which clinical trials may be impractical, or in which there is conflicting evidence.
The ADA funds development of the Standards from its general revenues with no industry support or involvement. Details on the methodology, information about the committee members and their conflictof-interest disclosures, and the complete Standards can be downloaded at professional.diabetes.org /annals.
PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES: RECOMMENDATIONS
Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacologic agent for the treatment of type 2 diabetes (A rating). Long-term use of metformin may be associated with biochemical vitamin B 12 deficiency, and periodic measurement of vitamin B 12 levels should be considered in patients treated with metformin, especially those with anemia or peripheral neuropathy (B rating). Providers should consider initiating insulin therapy (with or without additional agents) in patients with newly diagnosed type 2 diabetes who are symptomatic, have a hemoglobin A 1c (HbA 1c ) level of 10% or greater, or have a blood glucose level of 16.7 mmol/L (300 mg/dL) or greater (E rating). If noninsulin monotherapy at the maximum tolerated dose does not achieve or maintain the HbA 1c target after 3 months, adding a second oral agent, a glucagon-like peptide-1 (GLP-1)-receptor agonist, or basal insulin should be considered (A rating). For patients with type 2 diabetes who are not achieving glycemic goals, insulin therapy should be instituted without delay (B rating). A patientcentered approach should be used to guide the choice of pharmacologic agents (E rating).
unless there are contraindications. It is effective, safe, and inexpensive and may reduce the risk for cardiovascular events and death (2) . A large meta-analysis (3) supports the use of metformin monotherapy as first-line therapy. It may be safely used in patients with an estimated glomerular filtration rate as low as 30 mL/min/ 1.73 m 2 (4); the U.S. label of metformin was recently revised to reflect its safety in patients with an estimated glomerular filtration rate of 30 mL/min/1.73 m 2 or greater (5).
Gastrointestinal side effects are common in patients receiving metformin. In the authors' experience, these side effects can be reduced if metformin monotherapy is started at a dose of 500 mg once or twice daily with food and titrated gradually to the maximum effective dose (2 g/d). Patients should be advised to stop taking their medication if they experience nausea, vomiting, or dehydration.
The Diabetes Prevention Program Outcomes Study found that long-term users of metformin may develop vitamin B 12 deficiency. Periodic testing of vitamin B 12 levels should be considered in metformin users, especially those with anemia or peripheral neuropathy (6).
USING PHARMACOTHERAPIES OTHER THAN OR IN ADDITION TO METFORMIN
If the patient does not tolerate or has a contraindication to metformin, another option should be considered. The ADA/European Association for the Study of Diabetes position statement (7) recommends a patientcentered approach, including assessment of efficacy, hypoglycemia risk, effect on weight, side effects, cost, and patient preferences. A table detailing characteristics of all available glucose-lowering agents in the United States that may guide individualized treatment choices is available in section 8 of the Standards (8) . Tables 1 and 2 depict the costs of antihyperglycemic agents that were extracted from the Red Book (9) . With so many choices, patients and providers should be able to find a mutually agreeable treatment option.
For patients with an HbA 1c level of 9% or greater who are not acutely symptomatic, initiation of dual combination therapy (Figure 1) should be considered to more quickly achieve the target HbA 1c level. If the patient has a random glucose level of 16.7 mmol/L (300 mg/dL) or greater or an HbA 1c level of 10% or greater and has acute symptoms of polyuria, polydipsia, or 
ASSESSING RESPONSE AND DECIDING TO INTENSIFY THERAPY
Providers should assess whether the HbA 1c target has been achieved within approximately 3 months of therapy initiation ( Figure 1) ; if it has not, therapy should be intensified ( Figure 2 ). They should use shared decision making and a patient-centered approach when selecting a second agent. Potential combination therapies include a sulfonylurea, thiazolidinedione, dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium-glucose contransporter-2 (SGLT-2) inhibitor, GLP-1-receptor agonist, or basal insulin. Insulin should also be considered as part of any combination regimen for patients with severe hyperglycemia, especially if symptoms or catabolic features (such as weight loss or ketosis) are present. Patients should be reassessed within 3 months for achievement of the HbA 1c target.
RECENT EVIDENCE FROM CARDIOVASCULAR OUTCOMES TRIALS
Major cardiovascular outcomes trials have studied patients with type 2 diabetes and established cardiovascular disease, including EMPA-REG (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) (10) and the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial (11) . These 2 studies found that, compared with placebo and standard treatment, empagliflozin and liraglutide reduced composite outcomes for myocardial infarction, stroke, and cardiovascular death in populations in which most, if not all, patients had established atherosclerotic cardiovascular disease. Whether other agents in the same class as empagliflozin and liraglutide have similar benefits, and whether the treatments benefit patients at lower risk for cardiovascular disease, is unknown.
Cardiovascular outcomes trial data for the DPP-4 inhibitors sitagliptin (12) , saxagliptin (13) , and alogliptin (14) showed no statistically significant differences in rates of major cardiovascular events between treatment and placebo groups.
RECENT WARNINGS ABOUT PHARMACOTHERAPIES
In May 2015, the U.S. Food and Drug Administration (FDA) issued a warning that SGLT-2 inhibitors may lead to ketoacidosis in the absence of significant hyperglycemia (termed "euglycemic diabetic ketoacidosis"). Patients who develop symptoms of ketoacidosis, which may include dyspnea, nausea, vomiting, and abdominal pain, should stop taking SGLT-2 inhibitors and immediately seek medical attention (15) .
In April 2016, the FDA also warned that the DPP-4 inhibitors saxagliptin and alogliptin may increase the risk for heart failure, especially in patients with preexisting heart failure or renal impairment (16) .
INSULIN THERAPY
Diabetes is a progressive condition, and many patients with type 2 diabetes eventually require and benefit from insulin therapy. Early patient education about expected disease progression, and avoidance of threats of future insulin therapy (because it makes the expected transition more difficult), is important. Comprehensive education about blood glucose monitoring, nutrition, and hypoglycemia recognition and treatment are critical to patients receiving insulin therapy. Empowering patients with self-titration algorithms based on self-monitoring can improve glucose control in those with type 2 diabetes initiating insulin therapy (17) .
A safe and simple approach is to prescribe 10 units, or 0.1 to 0.2 units/kg of body weight, of basal insulin per day and advise to increase the dose by 10% to 15%, or 2 to 4 units, once or twice weekly until the fasting blood glucose target is met. Insulin is typically level is less than 8%. Providers should consider decreasing the basal insulin dose by the same amount of the starting mealtime dose.
Premixed insulin products containing both basal and bolus insulin are another option for patients who may benefit from simpler dosing. These contain a fixed proportion of basal and prandial insulin to target both fasting and postprandial glycemia. The main disadvantage is that this approach requires a relatively fixed meal schedule and carbohydrate content per meal.
Concentrated Insulin Products
Several concentrated insulin preparations are available. The U-500 formulation of regular insulin is, by definition, 5 times as concentrated as the U-100 formula- The order in the chart was determined by historical availability and the route of administration, with injectables to the right; it is not meant to denote any specific preference. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, with the usual transition moving vertically from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). Adapted with permission from Inzucchi and colleagues (7). DPP-4-i = dipeptidyl peptidase-4 inhibitor; GI = gastrointestinal; GLP-1-RA = glucagonlike peptide-1-receptor agonist; GU = genitourinary; HbA 1c = hemoglobin A 1c ; HF = heart failure; SGLT-2-i = sodium-glucose contransporter-2 inhibitor. * See Dieuzeide and colleagues (21) for description of efficacy and cost categorizations. † Usually a basal insulin (such as neutral protamine Hagedorn, glargine, detemir, or degludec).
Pharmacologic Therapy for Type 2 Diabetes CLINICAL GUIDELINE tion. The former has a delayed onset and longer duration of action than the latter and has both prandial and basal properties. U-500 insulin is indicated for patients requiring more than 200 units of insulin per day. U-300 glargine and U-200 degludec have longer durations of action than their U-100 formulations, which allow for higher doses of basal insulin per volume. The FDA has also approved a concentrated formulation of rapid-acting insulin called lispro U-200, which may be more suitable for some patients because the volume of 
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insulin being injected is significantly less than U-100 insulins. It may also improve adherence for those who require large doses of insulin. However, concentrated insulins may be more expensive than U-100 insulins. Although U-500 regular insulin is available in both prefilled pens and vials, other concentrated insulins are available only in prefilled pens to minimize the risk for dosing errors. In July 2016, the FDA approved a dedicated syringe for administering U-500 regular insulin from vials to help mitigate the risk for dosing errors.
Inhaled Insulin
Inhaled insulin is available for prandial use with a more limited dosing range. It is contraindicated in patients with chronic lung disease, such as asthma and chronic obstructive pulmonary disease, and is not recommended for smokers or those who recently stopped smoking. It requires spirometry to identify potential lung disease in all patients before and after initiation of therapy.
Combination Injectable Therapy
If basal insulin has been titrated to an acceptable fasting blood glucose level (or if the dose is >0.5 U/kg per day) and the HbA 1c level remains above target, combination injectable therapy should be considered ( Figure 2 ) (6). When this therapy is initiated, metformin therapy should be continued but other oral agents may be discontinued on an individual basis to avoid unnecessarily complex or costly regimens. Sulfonylureas, DPP-4 inhibitors, and GLP-1-receptor agonists may be continued or added to basal insulin therapy but are typically discontinued if a basal bolus or multiple-dose premixed insulin regimen is used. In patients with suboptimal blood glucose control, especially those requiring large doses of insulin, adjunctive use of a thiazolidinedione or SGLT-2 inhibitor may improve control and reduce the amount of insulin, although potential side effects should be considered. Once an insulin regimen is initiated, dose titration is important; dosing adjustments may be necessary in both mealtime and basal insulins, based on blood glucose level and an understanding of the pharmacodynamic profile of each formulation (that is, pattern control).
Further options for treatment intensification include adding a single injection of rapid-acting insulin analogue (lispro, aspart, or glulisine) before the largest meal, adding a GLP-1-receptor agonist, or stopping basal insulin and starting twice-daily premixed (or biphasic) insulin (such as 70/30 NPH/regular insulin mix, 70/30 aspart mix, or a 75/25 or 50/50 lispro mix). Administration is usually before breakfast and before dinner. A final option is once-or twice-daily 70/30 degludec/aspart mix taken before meals. Studies have shown the noninferiority of basal insulin plus a single injection of rapid-acting insulin administered at the largest meal compared with basal insulin plus a GLP-1-receptor agonist or 2 daily injections of premixed insulins ( Figure  2) . Basal insulin plus a GLP-1-receptor agonist is associated with weight loss and less hypoglycemia but may be more poorly tolerated and expensive than regimens using insulin alone (19, 20) . The FDA recently approved 2 once-daily, fixed-ratio combination products containing basal insulin plus a GLP-1-receptor agonist-lixisenatide plus insulin glargine, and liraglutide plus insulin degludec. Both approaches have advantages and disadvantages. Providers can consider regimen flexibility when devising a plan for the initiation and adjustment of insulin therapy for patients with type 2 diabetes. For example, rapid-acting insulin offers greater flexibility in meal planning than premixed insulin. If one regimen does not achieve HbA 1c targets (for example, basal insulin plus a GLP-1-receptor agonist), another regimen should be considered (for example, basal insulin plus a single injection of rapid-acting insulin or twice-daily premixed insulin) (21, 22) . Regular insulin and 70/30 NPH/regular insulin mix are less costly alternatives to rapid-acting and premixed insulin analogues, respectively, but their pharmacodynamic profiles may make them suboptimal. Figure 2 also outlines recommendations for further intensification, if needed, to achieve glycemic goals. If patients who receive basal insulin plus a single injection of rapid-acting insulin before the largest meal still exceed their HbA 1c target, they should advance to a basal-bolus insulin regimen with 2 or more injections of rapid-acting insulin before meals. Providers should consider switching patients who receive twice-daily premixed insulin and still exceed their HbA 1c target to thrice-daily premixed insulin analogues (70/30 aspart mix or a 75/25 or 50/50 lispro mix). In general, these analogues have been found to be noninferior to basalbolus insulin regimens with similar rates of hypoglycemia (23) . If the HbA 1c targets are not being met or there are other patient considerations, providers should consider switching regimens (that is, from thrice-daily premixed insulin analogue to a basal-bolus insulin regimen or vice versa) (21, 22) .
